Drug intelligence / Profile preview

HT006.2.2

Development stage: Unknown
Lead developer: Wuhan Hiteck Biological Pharma
Modality: Small Molecules
Administration: Ophthalmic

Overview

HT006.2.2 is an investigational small molecule drug developed by Wuhan Hiteck Biological Pharma that acts as a TrkA activator and p75NTR agonist, targeting neurotrophin signaling pathways involved in neuronal survival and function[1][6]. It is currently in Phase 1 clinical development for the treatment of keratitis, a condition characterized by inflammation of the cornea[6][10]. The dual action on TrkA (tropomyosin receptor kinase A) and p75NTR (p75 neurotrophin receptor) suggests potential for modulating nerve growth factor pathways relevant to ocular or neurological diseases.

Targets

NGFR (p75NTR)NTRK1 (Tropomyosin-related receptor kinase A)

Beyond the preview

Go deeper on HT006.2.2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HT006.2.2.

Explore the full profile